JP2010510177A - タンパク質フォールディング障害を治療するための化合物および方法 - Google Patents

タンパク質フォールディング障害を治療するための化合物および方法 Download PDF

Info

Publication number
JP2010510177A
JP2010510177A JP2009536575A JP2009536575A JP2010510177A JP 2010510177 A JP2010510177 A JP 2010510177A JP 2009536575 A JP2009536575 A JP 2009536575A JP 2009536575 A JP2009536575 A JP 2009536575A JP 2010510177 A JP2010510177 A JP 2010510177A
Authority
JP
Japan
Prior art keywords
compound
halogen
group
pharmaceutically acceptable
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009536575A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010510177A5 (enExample
Inventor
カーター，マイケル，ディー．
ウィーバー，ドナルド，エフ．
ジャコボ，シーラ，マリー，エイチ．
ルー，アーフ
ガオ，フーイェ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Queens University at Kingston
Original Assignee
Queens University at Kingston
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Queens University at Kingston filed Critical Queens University at Kingston
Publication of JP2010510177A publication Critical patent/JP2010510177A/ja
Publication of JP2010510177A5 publication Critical patent/JP2010510177A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/74—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C215/76—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton of the same non-condensed six-membered aromatic ring
    • C07C215/82—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the amino groups further bound to a carbon atom of another six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/78—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C217/80—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings
    • C07C217/82—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring
    • C07C217/92—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring the nitrogen atom of at least one of the amino groups being further bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/21—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Furan Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2009536575A 2006-11-17 2007-11-19 タンパク質フォールディング障害を治療するための化合物および方法 Pending JP2010510177A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85963206P 2006-11-17 2006-11-17
PCT/CA2007/002096 WO2008058402A1 (en) 2006-11-17 2007-11-19 Compounds and methods for treating protein folding disorders

Publications (2)

Publication Number Publication Date
JP2010510177A true JP2010510177A (ja) 2010-04-02
JP2010510177A5 JP2010510177A5 (enExample) 2012-01-26

Family

ID=39401296

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009536575A Pending JP2010510177A (ja) 2006-11-17 2007-11-19 タンパク質フォールディング障害を治療するための化合物および方法

Country Status (5)

Country Link
US (2) US8362066B2 (enExample)
EP (1) EP2081892A4 (enExample)
JP (1) JP2010510177A (enExample)
CA (1) CA2668744C (enExample)
WO (1) WO2008058402A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101460470B (zh) 2006-05-30 2011-05-18 阿斯利康(瑞典)有限公司 作为dgat1抑制剂的1,3,4-二唑衍生物
AR069340A1 (es) * 2007-11-26 2010-01-13 Merck & Co Inc Antagonistas del receptor de angiotensina ii
JP5662803B2 (ja) 2007-12-20 2015-02-04 アストラゼネカ アクチボラグ Ｄｇａｔ１阻害剤としてのカルバモイル化合物１９０
AU2010261499A1 (en) 2009-06-19 2012-01-12 Astrazeneca Ab Pyrazine carboxamides as inhibitors of DGAT1
TW201107315A (en) 2009-07-27 2011-03-01 Kissei Pharmaceutical Indole derivatives, or the pharmaceutically acceptable salts
GB0918249D0 (en) 2009-10-19 2009-12-02 Respivert Ltd Compounds
US8299070B2 (en) 2009-11-25 2012-10-30 Japan Tobacco Inc. Indole compounds and pharmaceutical use thereof
UY33337A (es) 2010-10-18 2011-10-31 Respivert Ltd DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
JP5937102B2 (ja) 2010-12-14 2016-06-22 エレクトロフォレティクス リミテッド カゼインキナーゼ１デルタ（ｃｋ１デルタ）阻害剤
JO3350B1 (ar) 2011-03-07 2019-03-13 Merck Sharp & Dohme مشتقات حلقية غير متجانسة محتوية على مجموعات أمينو أولية ومركبات داي أزينيومديولات
WO2012154888A1 (en) * 2011-05-09 2012-11-15 Proteostasis Therapeutics, Inc. Compounds for treating protein folding disorders
AU2013234081B2 (en) 2012-03-13 2017-02-02 Respivert Limited Crystalline PI3 kinase inhibitors
TWI638802B (zh) 2012-05-24 2018-10-21 芬蘭商奧利安公司 兒茶酚ｏ－甲基轉移酶活性抑制化合物
AR095353A1 (es) 2013-03-15 2015-10-07 Respivert Ltd Compuesto
TW201522341A (zh) 2013-03-15 2015-06-16 Respivert Ltd 化合物
US10328040B2 (en) 2014-01-17 2019-06-25 Arizona Board Of Regents On Behalf Of Arizona State University Therapeutic methods
AU2015211119B2 (en) * 2014-01-29 2019-05-30 Ucb Biopharma Sprl Heteroaryl amides as inhibitors of protein aggregation
US9908856B2 (en) 2014-02-26 2018-03-06 Arizona Board Of Regents On Behalf Of Arizona State University Therapeutic compounds
CN104844471B (zh) * 2015-04-21 2017-05-03 苏州远智医药科技有限公司 一种作为dor受体拮抗剂的化合物
WO2017117430A1 (en) * 2015-12-29 2017-07-06 The Scripps Research Institute Regulators of the endoplasmic reticulum proteostasis network
CN105669516B (zh) * 2016-03-09 2018-08-03 中山大学 一种3,3’-双吲哚化合物的制备方法
US10231947B2 (en) 2017-01-23 2019-03-19 Arizona Board Of Regents On Behalf Of Arizona State University Isochroman compounds and methods of use thereof
US10238655B2 (en) 2017-01-23 2019-03-26 Arizona Board Of Regents On Behalf Of Arizona State University Dihydroindene and tetrahydronaphthalene compounds
US10238626B2 (en) 2017-01-23 2019-03-26 Arizona Board Of Regents On Behalf Of Arizona State University Therapeutic compounds
CN113874015B (zh) 2018-12-21 2024-05-24 细胞基因公司 Ripk2的噻吩并吡啶抑制剂
KR102472137B1 (ko) * 2020-09-22 2022-11-30 가톨릭대학교 산학협력단 Nlrp3 인플라마좀 억제제 및 이의 용도
AU2022380979A1 (en) 2021-11-02 2024-06-06 Flare Therapeutics Inc. Pparg inverse agonists and uses thereof

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07188010A (ja) * 1993-12-01 1995-07-25 Eli Lilly & Co アミロイド形成タンパクの作用を抑制するための医薬組成物
JPH11228570A (ja) * 1998-02-20 1999-08-24 Taisho Pharmaceut Co Ltd ５−（置換フェニル）−４−（３−インドリル）イミダゾール誘導体
JP2004250411A (ja) * 2003-02-21 2004-09-09 Bf Kenkyusho:Kk アミロイドβ蓄積性疾患の診断プローブおよび治療用化合物
WO2004100998A2 (en) * 2003-05-07 2004-11-25 General Electric Company Compositions and methods for non-invasive imaging of soluble beta-amyloid
WO2005033059A1 (es) * 2003-10-08 2005-04-14 Innovaprotean, S.L. Compuestos útiles para el tratamiento de enfermedades asociadas a la formación de fibrilas amiloides
JP2005516935A (ja) * 2001-12-19 2005-06-09 アメルシャム・パブリック・リミテッド・カンパニー アルツハイマー病を造影するための化合物
JP2005526028A (ja) * 2002-02-06 2005-09-02 バーテックス　ファーマシューティカルズ　インコーポレイテッド Ｇｓｋ−３の阻害剤として有用なヘテロアリール化合物
JP2005534619A (ja) * 2002-03-28 2005-11-17 エーザイ株式会社 Ｃ−ｊｕｎｎ−末端キナーゼ阻害剤としてのアザインドール
JP2009511583A (ja) * 2005-10-11 2009-03-19 ユニバーシティー オブ ピッツバーグ アミロイド生成性タンパク質の造影剤としての同位体標識ベンゾフラン化合物
JP2010504326A (ja) * 2006-09-21 2010-02-12 ワイス エルエルシー β−セクレターゼを阻害するためのインドリルアルキルピリジン−２−アミン

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1282451B (de) * 1965-09-01 1968-11-07 Kalle Ag Lichtempfindliche Schicht und Verfahren zur Herstellung fixierter Bilder
JPS5113881A (en) * 1974-07-24 1976-02-03 Kanegafuchi Chemical Ind Enkabiniruno jugohoho
US4845079A (en) 1985-01-23 1989-07-04 Luly Jay R Peptidylaminodiols
US5066643A (en) 1985-02-19 1991-11-19 Sandoz Ltd. Fluorine and chlorine statine or statone containing peptides and method of use
US4894437A (en) 1985-11-15 1990-01-16 The Upjohn Company Novel renin inhibiting polypeptide analogs containing S-aryl-D- or L- or DL-cysteinyl, 3-(arylthio)lactic acid or 3-(arylthio)alkyl moieties
US4885292A (en) 1986-02-03 1989-12-05 E. R. Squibb & Sons, Inc. N-heterocyclic alcohol renin inhibitors
US5138069A (en) 1986-07-11 1992-08-11 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles
US4870186A (en) 1987-05-22 1989-09-26 E. I. Du Pont De Nemours And Company Tetrazole intermediates to antihypertensive compounds
US4874867A (en) 1987-05-22 1989-10-17 E. I. Du Pont De Nemours And Company Tetrazole intermediates to antihypertensive compounds
US4820843A (en) 1987-05-22 1989-04-11 E. I. Du Pont De Nemours And Company Tetrazole intermediates to antihypertensive compounds
US4980283A (en) 1987-10-01 1990-12-25 Merck & Co., Inc. Renin-inhibitory pepstatin phenyl derivatives
US5089471A (en) 1987-10-01 1992-02-18 G. D. Searle & Co. Peptidyl beta-aminoacyl aminodiol carbamates as anti-hypertensive agents
US5034512A (en) 1987-10-22 1991-07-23 Warner-Lambert Company Branched backbone renin inhibitors
US5063207A (en) 1987-10-26 1991-11-05 Warner-Lambert Company Renin inhibitors, method for using them, and compositions containing them
US5055466A (en) 1987-11-23 1991-10-08 E. R. Squibb & Sons, Inc. N-morpholino derivatives and their use as anti-hypertensive agents
US5036054A (en) 1988-02-11 1991-07-30 Warner-Lambert Company Renin inhibitors containing alpha-heteroatom amino acids
US5036053A (en) 1988-05-27 1991-07-30 Warner-Lambert Company Diol-containing renin inhibitors
DE3841520A1 (de) 1988-12-09 1990-06-13 Hoechst Ag Enzymhemmende harnstoffderivate von dipeptiden, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung
US5106835A (en) 1988-12-27 1992-04-21 American Cyanamid Company Renin inhibitors
US5063208A (en) 1989-07-26 1991-11-05 Abbott Laboratories Peptidyl aminodiol renin inhibitors
US5098924A (en) 1989-09-15 1992-03-24 E. R. Squibb & Sons, Inc. Diol sulfonamide and sulfinyl renin inhibitors
US5104869A (en) 1989-10-11 1992-04-14 American Cyanamid Company Renin inhibitors
US5114937A (en) 1989-11-28 1992-05-19 Warner-Lambert Company Renin inhibiting nonpeptides
US5064965A (en) 1990-03-08 1991-11-12 American Home Products Corporation Renin inhibitors
US5095119A (en) 1990-03-08 1992-03-10 American Home Products Corporation Renin inhibitors
US5075451A (en) 1990-03-08 1991-12-24 American Home Products Corporation Pyrrolimidazolones useful as renin inhibitors
US5039814A (en) 1990-05-02 1991-08-13 Merck & Co., Inc. Ortho-lithiation process for the synthesis of 2-substituted 1-(tetrazol-5-yl)benzenes
US5071837A (en) 1990-11-28 1991-12-10 Warner-Lambert Company Novel renin inhibiting peptides
US5130439A (en) 1991-11-18 1992-07-14 Lo Young S Tetrazolylphenylboronic acid intermediates for the synthesis of AII receptor antagonists
US5206374A (en) 1991-11-18 1993-04-27 E. I. Du Pont De Nemours And Company Process for preparing tetrazolylphenylboronic acid intermediates
US5310928A (en) 1991-11-18 1994-05-10 E. I. Du Pont De Nemours And Company Process for preparing biphenyltetrazole compounds
FR2688501B1 (fr) * 1992-03-13 1995-06-23 Oreal Compositions de teinture des fibres keratiniques a base de monoindolyl 1,4-naphtoquinones ou leurs leucoderives, nouveaux composes monoindolyl 1,4-naphtoquinones et leurs leucoderives.
ES2173433T3 (es) 1996-10-29 2002-10-16 Merck & Co Inc Procedimiento para la cristalizacion de losartan.
CA2496859A1 (en) * 1998-05-04 1999-11-11 Zentaris Gmbh Indole derivatives and their use for the treatment of malignant and other diseases based on pathological cell proliferation
US6399780B1 (en) * 1999-08-20 2002-06-04 Cephalon, Inc. Isomeric fused pyrrolocarbazoles and isoindolones
CA2357450A1 (en) * 2000-09-29 2002-03-29 Warner-Lambert Company Phenoxazine analogs useful as amyloid aggregation inhibitors and treatment of alzheimer's disease and disorders related to amyloidosis
CN1271068C (zh) * 2003-03-25 2006-08-23 上海医药工业研究院 一种奥美沙坦酯的制备方法
JP2007500684A (ja) 2003-07-31 2007-01-18 ニコックス エス エイ 心臓血管疾患治療用のアンギオテンシン−ｉｉ受容体遮断薬としてのロサルタン、バルサルタン、カンデサルタン、テルミサルタン、エプロサルタンおよびオルメサルタンのニトロオキシ誘導体
CA2536975A1 (en) 2003-08-28 2005-03-17 Nitromed, Inc. Nitrosated and nitrosylated diuretic compounds, compositions and methods of use
EP1711454A4 (en) 2004-01-27 2007-04-04 Merck Frosst Company COMBINATION THERAPY FOR TREATING DISEASES OR CONDITIONS INDUCED BY CYCLOOXYGENASE-2 IN PATIENTS WITH RISK OF THROMBOTIC CARDIOVASCULAR EVENTS
WO2005077343A2 (de) * 2004-02-11 2005-08-25 Max-Delbrück-Centrum für Molekulare Medizin Neue arzneimittel und diagnostische zusammensetzungen für behandlung und diagnose von neurodegenerativen erkrankungen und amyloid-krankheiten
WO2006047514A2 (en) * 2004-10-25 2006-05-04 Whitehead Institute For Biomedical Research Daph analogs and inhibition of protein aggregation
WO2006125324A1 (en) * 2005-05-27 2006-11-30 Queen's University At Kingston Treatment of protein folding disorders

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07188010A (ja) * 1993-12-01 1995-07-25 Eli Lilly & Co アミロイド形成タンパクの作用を抑制するための医薬組成物
JPH11228570A (ja) * 1998-02-20 1999-08-24 Taisho Pharmaceut Co Ltd ５−（置換フェニル）−４−（３−インドリル）イミダゾール誘導体
JP2005516935A (ja) * 2001-12-19 2005-06-09 アメルシャム・パブリック・リミテッド・カンパニー アルツハイマー病を造影するための化合物
JP2005526028A (ja) * 2002-02-06 2005-09-02 バーテックス　ファーマシューティカルズ　インコーポレイテッド Ｇｓｋ−３の阻害剤として有用なヘテロアリール化合物
JP2005534619A (ja) * 2002-03-28 2005-11-17 エーザイ株式会社 Ｃ−ｊｕｎｎ−末端キナーゼ阻害剤としてのアザインドール
JP2004250411A (ja) * 2003-02-21 2004-09-09 Bf Kenkyusho:Kk アミロイドβ蓄積性疾患の診断プローブおよび治療用化合物
WO2004100998A2 (en) * 2003-05-07 2004-11-25 General Electric Company Compositions and methods for non-invasive imaging of soluble beta-amyloid
WO2005033059A1 (es) * 2003-10-08 2005-04-14 Innovaprotean, S.L. Compuestos útiles para el tratamiento de enfermedades asociadas a la formación de fibrilas amiloides
JP2009511583A (ja) * 2005-10-11 2009-03-19 ユニバーシティー オブ ピッツバーグ アミロイド生成性タンパク質の造影剤としての同位体標識ベンゾフラン化合物
JP2010504326A (ja) * 2006-09-21 2010-02-12 ワイス エルエルシー β−セクレターゼを阻害するためのインドリルアルキルピリジン−２−アミン

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6011007661; ＬＥＣＬＥＲＣ Ｓ． 他: 'Ｉｎｄｉｒｕｂｉｎｓ Ｉｎｈｉｂｉｔ Ｇｌｙｃｏｇｅｎ Ｓｙｎｔｈａｓｅ Ｋｉｎａｓｅ-３ｂｅｔａ ａｎｄ ＣＤＫ５／Ｐ２５， Ｔｗｏ Ｐｒｏｔｅｉｎ Ｋｉｎａｓｅｓ Ｉｎｖｏｌｖｅｄ ｉｎ Ａｂｎｏ' Ｊ． ＢＩＯＬ． ＣＨＥＭ． ｖｏｌ． ２７６， ｎｏ． １, 2001, ２５１-２６０頁 *

Also Published As

Publication number Publication date
EP2081892A1 (en) 2009-07-29
US7834042B2 (en) 2010-11-16
WO2008058402A1 (en) 2008-05-22
CA2668744A1 (en) 2008-05-22
US20100144821A1 (en) 2010-06-10
EP2081892A4 (en) 2014-03-05
CA2668744C (en) 2015-09-15
US8362066B2 (en) 2013-01-29
US20100152258A1 (en) 2010-06-17

Similar Documents

Publication Publication Date Title
JP2010510177A (ja) タンパク質フォールディング障害を治療するための化合物および方法
CA2609980C (en) Treatment of protein folding disorders
Santos et al. Recent progress in repositioning Alzheimer's disease drugs based on a multitarget strategy
JP5657556B2 (ja) α７選択的リガンドを用いる治療
IL292968B1 (en) Fused bicyclic scg stimulators
JP2006521377A (ja) 新型ｉｄｏ阻害剤とその使用方法
AU2015336458B2 (en) KCNQ2-5 channel activator
JP2002515012A (ja) グリシン／ｎｍｄａ受容体アンタゴニストのアザおよびアザ（ｎ−オキシ）類似体
CN112010827A (zh) 一类苄胺基苯酞类化合物、其制备方法和用途
CN110156674A (zh) 一种作为吲哚胺-2,3-双加氧酶抑制剂的螺环化合物
JP6302480B2 (ja) 中枢神経系疾患の治療に有用なトリアゾロ−ピラジン誘導体
JP2001131151A (ja) オレフィン誘導体の新規用途
TWI592399B (zh) 菸鹼乙醯膽鹼受體之新穎正向異位調節劑
KR102628396B1 (ko) 샤프롱-매개 자가포식 조절제로서 유용한 화합물
CN116615193A (zh) 作为选择性fabp5抑制剂的吐昔酸单酯衍生物和药物组合物及其用途
TW202019886A (zh) 雜芳基類衍生物、其製備方法及其在醫藥上的應用
JP6321274B2 (ja) トリプル再取込み阻害剤及びそれらの使用方法
JP2019512550A (ja) エストロゲン受容体ダウンレギュレーターとしての置換インドール化合物
KR20150021120A (ko) 헤테로아릴 화합물 및 이의 이용 방법
JP2004522781A (ja) 腫瘍処置のためのプロドラッグとしてのインドリンおよびテトラヒドロ−キノリン
CN108409737B (zh) 4-甲氧基苯基取代四氢-β-咔啉哌嗪二酮类衍生物及其应用
CN108409738A (zh) 3,4-亚甲二氧基苯基取代四氢-β-咔啉哌嗪二酮类衍生物及其用途
JP2025512815A (ja) ヒストン脱アセチル化酵素６阻害剤としての１，３，４－オキサジアゾール誘導体化合物およびその用途
FR3067028B1 (fr) Modulateurs de recepteurs nmda, compositions les comprenant et utilisation de ces composes dans le traitement de maladies impliquant le systeme nerveux central
Zakurdaev et al. Mild and regioselective straightforward synthesis of isomelatonin analogues

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101110

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20101110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120106

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20120106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20120106

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20130129

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130205

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130723